14.11.2012 Aufrufe

Annual Report 2009/2010 Geschäftsbericht 2009/2010 ... - biolitec AG

Annual Report 2009/2010 Geschäftsbericht 2009/2010 ... - biolitec AG

Annual Report 2009/2010 Geschäftsbericht 2009/2010 ... - biolitec AG

MEHR ANZEIGEN
WENIGER ANZEIGEN

Sie wollen auch ein ePaper? Erhöhen Sie die Reichweite Ihrer Titel.

YUMPU macht aus Druck-PDFs automatisch weboptimierte ePaper, die Google liebt.

52 Management <strong>Report</strong> Konzernlagebericht<br />

Liquidity risks and risks from cash flow fluctuations<br />

The risk of a short-term liquidity shortage is observed by the management via liquidity monitoring.<br />

Therefore, the maturity of financial assets, especially accounts receivable and accounts payable as well<br />

as the expected operating cash flow are considered.<br />

Due to the momentary available liquidity together with the projected medium-term capital requirements<br />

the Executive Board sees no risks. There is a general risk of cash flow fluctuations, especially in<br />

cases of unexpected outcomes of legal disputes or due to unexpected negative changes on key markets.<br />

However, the Executive Board is convinced that even in such cases the disposable financial assets<br />

are sufficient to counter-balance such cash flow fluctuations and therefore sees no further risks.<br />

Investment risks<br />

Some of the subsidiaries’ existence is dependent on financing by the parent company or other subsidiaries.<br />

Especially the distribution company in the USA is refinanced this way. The net lendings/net borrowings<br />

of the group’s companies value in different currencies – often not even in functional currencies<br />

– and therefore a risk of currency conversions can be observed.<br />

A disclosure on the group’s legal risks can be found in the notes’ section “Process and Legal risks.”<br />

Anticipated company development<br />

Taking into account the aforementioned projected chances and risks, a positive business performance<br />

can be expected during the next two years. This evaluation is made under the premise that the market<br />

penetration of <strong>biolitec</strong>’s products can be increased through intensified distribution activities, the production<br />

related processes are optimized according to the developing technological standard as well as<br />

no unexpected legal disputes arise.<br />

Explanatory <strong>Report</strong> by the Executive Board on the pursuant to<br />

§§ 289 V, 315 II No. 5 of the German Commercial Code (HGB)<br />

Legal Background<br />

The Accounting Law Reform Act (BilMoG) enacted 29 May <strong>2009</strong> amended §§289, 315 of the German<br />

Commercial Code (Handelsgesetzbuch, HGB) and §§120, 175 German Stock Corporation Act<br />

(Aktiengesetz,AktG). Pursuant to the Reform Act, the Executive Board must present a written report to<br />

shareholders at the <strong>Annual</strong> General Meeting on matters including the new disclosure requirements in<br />

the management report per §289 V HGB and in the Group management report per §315 II No. 5 HGB<br />

regarding the internal control and risk management system in place for the accounting and consolidated<br />

accounting process.<br />

In the later German Act Implementing the Shareholders’ Rights Directive (Gesetz zur Umsetzung der<br />

Aktionärsrichtlinie – ARUG) legislators bundled requirements for providing explanatory reports under §<br />

176 I Sentence 1 AktG and eliminated the previous regulations under §120 III Sentence 2 and §175 II<br />

Sentence 1 AktG. The reference to §289 V HGB added by BilMoG and the management report disclosures<br />

on the internal control and risk management system in place for the accounting and consolidated<br />

accounting process were not incorporated. On the other hand, the German Department of Justice

Hurra! Ihre Datei wurde hochgeladen und ist bereit für die Veröffentlichung.

Erfolgreich gespeichert!

Leider ist etwas schief gelaufen!